

Resource Summary Report

Generated by [RRID](#) on Jul 28, 2026

NF-kappaB2 p100/p52 Antibody

RRID:AB_10695537

Type: Antibody

Proper Citation

Cell Signaling Technology Cat# 4882, RRID:AB_10695537

Antibody Information

URL: http://antibodyregistry.org/AB_10695537

Proper Citation: Cell Signaling Technology Cat# 4882, RRID:AB_10695537

Target Antigen: NF-kappaB2 p100/p52

Host Organism: rabbit

Clonality: polyclonal

Comments: Applications: W, IP. Consolidation on 11/2018: AB_10695537, AB_10828354, AB_2153403.

Antibody Name: NF-kappaB2 p100/p52 Antibody

Description: This polyclonal targets NF-kappaB2 p100/p52

Target Organism: rat, h, m, mouse, r, human, mk

Antibody ID: AB_10695537

Vendor: Cell Signaling Technology

Catalog Number: 4882

Record Creation Time: 20250819T222332+0000

Record Last Update: 20250820T020249+0000

Ratings and Alerts

No rating or validation information has been found for NF-kappaB2 p100/p52 Antibody.

No alerts have been found for NF-kappaB2 p100/p52 Antibody.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 30 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Chen C, et al. (2026) B cells disrupt tertiary lymphoid structure formation and suppress anti-tumor immunity. Cancer cell.

Goyal S, et al. (2025) Bacterial ADP-heptose triggers stem cell regeneration in the intestinal epithelium following injury. Cell stem cell, 32(8), 1235.

Shemorry A, et al. (2025) Engineering ER γ degraders with pleiotropic ubiquitin ligase ligands maximizes therapeutic efficacy by co-opting distinct effector ligases. Cell chemical biology, 32(5), 694.

Tang D, et al. (2025) Augment proteasome inhibitor efficacy activates CD8 $^{+}$ T cell-mediated antitumor immunity in breast cancer. Cell reports. Medicine, 6(7), 102211.

Ghosh A, et al. (2025) Potentiation of noncanonical NF- κ B signaling and marginal zone B cell expansion by CARD11-mediated regulation of p100 processing. Cell reports, 44(12), 116616.

Liu L, et al. (2025) TWEAK-Fn14 signaling protects mice from pulmonary fibrosis by inhibiting fibroblast activation and recruiting pro-regenerative macrophages. Cell reports, 44(2), 115220.

Martínez Villarreal A, et al. (2025) Memory T-Cell Phenotype in Cutaneous T-Cell Lymphoma Is Modified by Germline Gene Gametocyte Specific Factor 1. Experimental dermatology, 34(5), e70123.

Zheng K, et al. (2025) Mask protein keeps NF- κ B precursor inactive by inducing a closed conformation and isolating it in biomolecular condensates. Cell reports, 44(9), 116225.

Zhou L, et al. (2025) Lipid droplet efferocytosis attenuates proinflammatory signaling in macrophages via TREM2- and MS4A7-dependent mechanisms. Cell reports, 44(2), 115310.

Liang X, et al. (2025) Limited activation interdependence and differing patterns of the in vivo effects of IKK1 and IKK2 downstream of NIK. Cell reports, 44(10), 116404.

Anany MA, et al. (2025) Valence and avidity determine the agonistic activity of anti-TNFR2 nanobody fusion proteins. Cell chemical biology.

Gitlin AD, et al. (2024) N4BP1 coordinates ubiquitin-dependent crosstalk within the I κ B kinase family to limit Toll-like receptor signaling and inflammation. Immunity, 57(5), 973.

Yan HF, et al. (2024) Cell density impacts the susceptibility to ferroptosis by modulating IRP1-mediated iron homeostasis. *Journal of neurochemistry*, 168(7), 1359.

Domaniku-Waraich A, et al. (2024) Oncostatin M signaling drives cancer-associated skeletal muscle wasting. *Cell reports. Medicine*, 5(4), 101498.

You E, et al. (2024) Disruption of cellular plasticity by repeat RNAs in human pancreatic cancer. *Cell*, 187(25), 7232.

Lan Y, et al. (2023) IRP1 mediated ferroptosis reverses temozolomide resistance in glioblastoma via affecting LCN2/FPN1 signaling axis depended on NFKB2. *iScience*, 26(8), 107377.

Afsahi A, et al. (2023) LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling. *Frontiers in immunology*, 14, 1179827.

Dardis GJ, et al. (2023) An EZH2-NF- κ B regulatory axis drives expression of pro-oncogenic gene signatures in triple negative breast cancer. *iScience*, 26(7), 107115.

Xie J, et al. (2023) The miR-17-92 miRNAs promote plasma cell differentiation by suppressing SOCS3-mediated NIK degradation. *Cell reports*, 42(8), 112968.

Lin XT, et al. (2023) Elevated FBXW10 drives hepatocellular carcinoma tumorigenesis via AR-VRK2 phosphorylation-dependent GAPDH ubiquitination in male transgenic mice. *Cell reports*, 42(7), 112812.